The DUO-CARE blood glucose and blood pressure measurement system consists of a meter with wrist cuff and test strips. The system is intended for use in the quantitative measurement of glucose in whole blood taken from the fingertip. Testing is done outside the body (In Vitro diagnostic use). It is indicated for use at home (over the counter [OTC]) by persons with diabetes mellitus, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control. It is not intended for use on neonates.

Also the system measures systolic and diastolic blood pressure and pulse rate from adult's wrist in the home care environment. The device employs a wrist cuff and the oscillometric method of measurement.

The system includes optional accessory software that is installed on the users' computers for data management purposes.

Device Description

DUO-CARE Genexel-Sein Blood Glucose & Pressure Monitor system combines the function of a blood glucose monitoring system and a blood pressure meter in one unit. Supplies with the meter are test strips, lancets, lancing device, storage case and control solution. The blood glucose monitoring system is turned on by strip insertion; Once the user confirms that the numerical code on the display, and strip bottle all match, a test strip is inserted into the meter and glucose testing can proceed. The user then supplies finger-tip or control solution to the strip and the meter starts the measurement, which is completed in 5 seconds. Genexel-Sein, Inc has provided instructions and illustrations explaining, that the blood drop will be pulled into the strip sample entry by capillary action until meter beeps and the result will be show on liquid crystal display ("LCD") after 5 seconds. Results are automatically stored in the meter's memory for tracking purposes. The capacity of memory is 150 blood glucose values and average value of past 14 days or 30 days. Control Solution is sold separately from the kit.

DUO-CARE adopts the wrist type cuff for blood pressure meter part. The cuff and control unit are combined into a single wrist-mounted assembly. The user interface panel has power switch, mode switch, memory switch, for blood pressure meter part and LCD for displaying the systolic blood pressure, diastolic blood pressure, pulse rate, date and time. This device has the memory function that permits memory and display of the 60 most recent measurement results. User should wrap the pressure cuff around the wrist with the palm facing up and pushes the "Power" button. The cuff will with appropriate air pressure automatically. Pressurization is automatically governed. If the initial inflation pressure (180mmHg) is inadequate for measurement, i.e. lower that the patient's systolic pressure, the pump will automatically repressurize to a preset level (30 mmHg) above the initial level. Symbols in the LCD indicate pressurization status at all times. The air of cuff is automatically deflated during blood pressure measurement. No special training beyond basic ability to follow instruction is required. Since the products are designed for home use, detailed instructions on avoidance of practices that adversely affect the accuracy of measurements are included in the instruction manual.

AI/ML Overview

This 510(k) summary (K080853) is for a "BLOOD GLUCOSE AND BLOOD PRESSURE MONITOR SYSTEM, MODEL DUO-CARE." It describes a combined device for measuring blood glucose and blood pressure. The summary focuses on substantiating equivalence to a predicate device (K052108) rather than providing detailed acceptance criteria and study results for its own performance.

Therefore, many of the requested details about acceptance criteria, specific study design, and performance metrics are not available in the provided document. The document states "This device is safe and effective as the predicate device cited above. This is better expressed in the tabulated comparison," implying that the safety and effectiveness are established by demonstrating substantial equivalence to the predicate, rather than through a new, independent performance study with its own acceptance criteria detailed in this summary.

Here's the information that can be extracted or deduced from the provided text, with many fields explicitly marked as "Not provided" due to the nature of this 510(k) submission:

1. A table of acceptance criteria and the reported device performance

Acceptance Criteria	Reported Device Performance
Blood Glucose Monitoring:
(Specific accuracy criteria, e.g., ISO 15197 for glucose meters)	Not provided (Performance established by substantial equivalence to predicate device K052108)
Blood Pressure Monitoring:
(Specific accuracy criteria, e.g., AAMI/ISO standards for BP monitors)	Not provided (Performance established by substantial equivalence to predicate device K052108)

Explanation: The document states, "This device is safe and effective as the predicate device cited above." It does not provide specific acceptance criteria or performance numbers for the DUO-CARE device itself. The claim of safety and effectiveness relies on its "substantial equivalence" to the predicate device (K052108), meaning its performance characteristics are presumed to be similar enough to be considered safe and effective for its intended use.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

Test set sample size: Not provided.
Data provenance: Not provided.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

Not applicable/Not provided. The summary describes a medical device, not an AI or image-based diagnostic system where expert ground truth interpretation of a test set would be a primary method of validation for this type of 510(k) submission.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable/Not provided.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This device is a direct measurement device (blood glucose and blood pressure monitor), not an AI-assisted diagnostic tool that would involve human "readers."

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

Not applicable for a combined blood glucose and blood pressure monitor in the context of this 510(k) submission. The device is intended for direct measurement. While it has optional software for data management, the primary "performance" is the measurement itself, which is inherently "standalone" in its function.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

Not explicitly stated for the DUO-CARE device. For blood glucose and blood pressure monitors, ground truth is typically established by comparing device readings to a highly accurate laboratory reference method or a clinically validated reference device. This 510(k) relies on the substantial equivalence to a predicate device, which would have undergone such validation.

8. The sample size for the training set

Not applicable. This is a measurement device, not an AI model requiring a training set in the conventional sense.

9. How the ground truth for the training set was established

Not applicable.

Summary

{0}------------------------------------------------

510(k) Summary

K080853

As Required by 21 section 807.92 ( c )

1- Submitter Name:	Genexel-Sein, Inc (formerly Sein Electronics Co., Ltd)
2- Address:	111 Yangjae-Dong, Seocho-Gu, Seoul, Korea06833

November 20, 2008

111 Yangjae-Dong, Seocho-Gu, Seoul, Korea FEB 2 0 2009

82 2 575 1141 3- Phone:
82 2 575 1668 4- Fax:

Won Ky Kim, Director of R&D 5- Contact Person:

6- Date summary prepared:
7 - Official Correspondent:

Mansour Consulting LLC 845 Aronson Lake Court. Roswell, GA 30075 USA

8- Address:
678-908-8180 9- Phone: 678-623-3765
10- Fax:
11- Contact Person: Jay Mansour, President

12- Device Trade or Proprietary Name: BLOOD GLUCOSE AND BLOOD PRESSURE MONITOR SYSTEM, MODEL DUO-CARE

13- Device Common or usual name: Blood Glucose Monitor, Blood glucose test strips, quality control material, and Blood Pressure Monitor

14- Device Classification Name:

System. test, blood glucose, over the counter

Glucose oxidase, glucose
Single (specified) analyte controls

System, measurement, blood-pressure, non-invasive

15- Substantial Equivalency is claimed against 510K #K052108

16- Description of the Device:

Aイイタビがりしけて 11

{1}------------------------------------------------

17- Intended use of the device: (refer to FDA form attached)

method on houdes optional accessory software that is installed on the users' computers for data management purposes.

18- Safety and Effectiveness of the device:

This device is safe and effective as the predicate device cited above. This is better expressed in the tabulated comparison (Paragraph 14 below)

14- Summary comparing technological characteristics with predicate device:

Please find below a tabulated comparison supporting that this device is substantially equivalent to other medical devices in commercial distribution. Also, Equivalency overview chart path is to other modious . In the surve is SUBSTANTIALLY EQUIVALENT to the predicate device. Refer to the explanations/details within the main submission.

FDA file reference number	510k # K052108
TECHNOLOGICAL CHARACTERISTICS	Comparison result
Indications for use	IDENTICAL
Target population
Design
Materials
Performance
Sterility
Biocompatibility
Mechanical safety
Chemical safety
Anatomical sites
Human factors	VERY SIMILAR (USB CABLE ADDED TO TRANSMIT MEASURED DATA TO PC, SOFTWARE ADDED AT PC SIDE)
Energy used and/or delivered
Compatibility with environment and other devices
Where used	IDENTICAL
Standards met
Electrical safety
Thermal safety
Radiation safety

Refer to the submission for more details.

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized depiction of an eagle with outstretched wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.

Public Health Service

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Genexel-Sein, Inc. c/o Jay Mansour Mansour Consulting, LLC 845 Aronson Lake Court Roswell, GA 30075

FEB 2 0 2009

Re: K080853 Trade/Device Name: DUO-CARE Regulation Number: 21CFR 862.1345 Regulation Name: Glucose Test System Regulatory Class: Class II Product Code: NBW, CGA, JJX, DXN Dated: February 3, 2009 Received: February 12, 2009

Dear Mr. Mansour:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21; Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{3}------------------------------------------------

Page - 2

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permorts your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll free number (800) 638-2041 or (301) 443-6597 or at its Internet address

http://www.fda.gov/cdrh/dsma/dsmamain.html:

Sincerely yours.

Coy C. Hh

Courtney C. Harper, Ph.D. Acting Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

{4}------------------------------------------------

Indication for Use

510(k) Number (if known): K080853

Device Name: DUO-CARE

Indication For Use:

The DUO-CARE blood glucose and blood pressure measurement system consists of a meter with wrist cuff and test strips. The system is intended for use in the quantitative measurement of glucose in whole blood taken from the fingertip. Testing is done outside the body (In Vitro diagnostic use). It is indicated for use at home (over the counter (OTC]) by persons with diabetes mellitus, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control. It is not intended for use on neonates.

of and ever system measures systolic and diastolic blood pressure and pulse rate from adult's wrist in the home care environment. The device employs a wrist cuff and the oscillometric method of measurement.

The system includes optional accessory software that is installed on the users' computers for data management purposes.

Prescription Üse V (21 CFR Part 801 Subpart D) Over the Counter Use v (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE, CONTINUE ON ANOTHER PAGE IF NEEDED)

And/Or

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OVD)

Rutll Chooln for Courtney Harper

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K080853

ATTACHMENT 10

Page 1 of 1

Regulation Number and Section

§ 862.1345 Glucose test system.

(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.